Taysha Gene Therapies, Inc. announced that it has entered into agreement for a private placement of common shares share for proceeds of $80,000,000 on October 21, 2022. The transaction will include participation from Astellas Pharma Inc. for 15% stake and Audentes Therapeutics, Inc. for 7,266,342 shares for proceeds of $30,009,992.46. The securities are subject to Regulation D.
Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.38% | 22.28B | |
-5.48% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |